94 related articles for article (PubMed ID: 1975263)
1. ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids.
Sias PE; Kotts CE; Vetterlein D; Shepard M; Wong WL
J Immunol Methods; 1990 Aug; 132(1):73-80. PubMed ID: 1975263
[TBL] [Abstract][Full Text] [Related]
2. ELISA for quantitation of L-selectin shed from leukocytes in vivo.
Spertini O; Schleiffenbaum B; White-Owen C; Ruiz P; Tedder TF
J Immunol Methods; 1992 Nov; 156(1):115-23. PubMed ID: 1385536
[TBL] [Abstract][Full Text] [Related]
3. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.
Lewis GD; Figari I; Fendly B; Wong WL; Carter P; Gorman C; Shepard HM
Cancer Immunol Immunother; 1993 Sep; 37(4):255-63. PubMed ID: 8102322
[TBL] [Abstract][Full Text] [Related]
4. The unique monoclonal antibodies and immunochemical assay for comprehensive determination of the cell-bound and soluble HER2 in different biological samples.
Antos A; Topolska-Woś A; Woś M; Mitura A; Sarzyńska P; Lipiński T; Kurylcio A; Ziółkowski P; Świtalska M; Tkaczuk-Włach J; Gamian A; Polkowski WP; Staniszewska M
Sci Rep; 2024 Feb; 14(1):3978. PubMed ID: 38368450
[TBL] [Abstract][Full Text] [Related]
5. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.
Vazquez-Martin A; Fernandez-Real JM; Oliveras-Ferraros C; Navarrete JM; Martin-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2009 Dec; 35(6):1369-76. PubMed ID: 19885560
[TBL] [Abstract][Full Text] [Related]
6. ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab.
Agnolon V; Contato A; Meneghello A; Tagliabue E; Toffoli G; Gion M; Polo F; Fabricio ASC
Sci Rep; 2020 Feb; 10(1):3016. PubMed ID: 32080226
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
Shepard HM; Lewis GD; Sarup JC; Fendly BM; Maneval D; Mordenti J; Figari I; Kotts CE; Palladino MA; Ullrich A
J Clin Immunol; 1991 May; 11(3):117-27. PubMed ID: 1679763
[TBL] [Abstract][Full Text] [Related]
8. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
Lennon S; Barton C; Banken L; Gianni L; Marty M; Baselga J; Leyland-Jones B
J Clin Oncol; 2009 Apr; 27(10):1685-93. PubMed ID: 19255335
[TBL] [Abstract][Full Text] [Related]
9. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer.
Fendly BM; Kotts C; Vetterlein D; Lewis GD; Winget M; Carver ME; Watson SR; Sarup J; Saks S; Ullrich A
J Biol Response Mod; 1990 Oct; 9(5):449-55. PubMed ID: 1979347
[TBL] [Abstract][Full Text] [Related]
10. [Changes in immune function of dendritic cells infected by recombinant adenovirus containing Her2/neu gene of extracellular and transmembrane domain proteins].
Ma SD; Luo RC; Ding ZH; Lu F; Yuan CQ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1184-7. PubMed ID: 16939917
[TBL] [Abstract][Full Text] [Related]
11. Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification.
Tagliabue E; Centis F; Campiglio M; Mastroianni A; Martignone S; Pellegrini R; Casalini P; Lanzi C; Ménard S; Colnaghi MI
Int J Cancer; 1991 Apr; 47(6):933-7. PubMed ID: 1672668
[TBL] [Abstract][Full Text] [Related]
12. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.
Hudziak RM; Lewis GD; Winget M; Fendly BM; Shepard HM; Ullrich A
Mol Cell Biol; 1989 Mar; 9(3):1165-72. PubMed ID: 2566907
[TBL] [Abstract][Full Text] [Related]
13. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage.
Pupa SM; Ménard S; Morelli D; Pozzi B; De Palo G; Colnaghi MI
Oncogene; 1993 Nov; 8(11):2917-23. PubMed ID: 8105438
[TBL] [Abstract][Full Text] [Related]
14. p185 HER2/neu epitope mapping with murine monoclonal antibodies.
Centis F; Tagliabue E; Uppugunduri S; Pellegrini R; Martignone S; Mastroianni A; Ménard S; Colnaghi MI
Hybridoma; 1992 Jun; 11(3):267-76. PubMed ID: 1379973
[TBL] [Abstract][Full Text] [Related]
15. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
Sarup JC; Johnson RM; King KL; Fendly BM; Lipari MT; Napier MA; Ullrich A; Shepard HM
Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187
[TBL] [Abstract][Full Text] [Related]
16. Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro.
Hosseini Ghatar R; Soltantoyeh T; Bahadori M; Khoshnoodi J; Golsaz Shirazi F; Jeddi Tehrani M; Amiri MM; Shokri F
Iran J Immunol; 2017 Sep; 14(3):200-214. PubMed ID: 28919583
[TBL] [Abstract][Full Text] [Related]
17. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
Colomer R; Montero S; Lluch A; Ojeda B; Barnadas A; Casado A; Massutí B; Cortés-Funes H; Lloveras B
Clin Cancer Res; 2000 Jun; 6(6):2356-62. PubMed ID: 10873087
[TBL] [Abstract][Full Text] [Related]
18. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.
Langton BC; Crenshaw MC; Chao LA; Stuart SG; Akita RW; Jackson JE
Cancer Res; 1991 May; 51(10):2593-8. PubMed ID: 1673637
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a manual ELISA kit for determination of HER2/neu in serum of breast cancer patients.
Gauchez AS; Ravanel N; Villemain D; Brand FX; Pasquier D; Payan R; Mousseau M
Anticancer Res; 2008; 28(5B):3067-73. PubMed ID: 19031958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
